Pharmacological and clinical aspects of fluvoxamine (Depromel), the first selective serotonin reuptake inhibitor approved for clinical use employed in Japan.

DOI Web Site PubMed 2 Citations 50 References
  • HACHISU Mitsugu
    Medical Research Department, Pharmaceutical Division, Meiji Seika Kaisha Ltd.
  • ICHIMARU Yasuyuki
    Medical Research Department, Pharmaceutical Division, Meiji Seika Kaisha Ltd.

Bibliographic Information

Other Title
  • 日本初の選択的セロトニン再取り込み阻害薬（ＳＳＲＩ）フルボキサミン（デプロメール）の臨床および薬理学的特性
  • シンヤク ショウカイ ソウセツ ニホン ハツ ノ センタクテキ セロトニン サイトリコミ ソガイヤク SSRI フルボキサミン デプロメール ノ リンショウ オヨビ ヤクリガクテキ トクセイ

Search this article

Description

Fluvoxamine (Depromel®), a selective serotonin reuptake inhibitor (SSRI), was launched in May 1999 in Japan with more than 10 years' delay from the marketing in Europe and the United States. Fluvoxamine has been approved in about 80 countries as the indication to “depression” since 1983. As the indication to obsessive-compulsive disorder (OCD), fluvoxamine was first approved in the United States in 1994 and then in about 30 countries. Efficacy of the drug on “depression and depressed state” was found to be comparable to traditional tricyclic antidepressants (TCAs) by the clinical studies in Japan. Indication to OCD was first approved for fluvoxamine in Japan. The antidepressant and the anti-OCD action are considered the result of the serotonin reuptake inhibition at the serotonergic neurons. Fluvoxamine has little affinity for muscarinic, adrenergicα1- and histamine Hl-receptors, which TCAs have. Therefore, fluvoxamine possesses less side effects such as dry mouse, disuria, dizziness, orthostatic hypotension and drowsiness, etc.; and it is useful for elderly patients and long-term treatments for depression and OCD.

Journal

Citations (2)*help

See more

References(50)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top